Specific and non-specific lymphocyte cytotoxicity in colon carcinoma - PubMed (original) (raw)

Specific and non-specific lymphocyte cytotoxicity in colon carcinoma

B M Vose et al. Br J Cancer. 1981 Dec.

Free PMC article

Abstract

The cytotoxic activity of peripheral-blood (PBL), lymph-node (LNC) and tumour-infiltrating lymphocytes (TIL) from 47 patients undergoing surgery for colon carcinoma (Duke's Stage A, 1 patient; B, 24; C, 15 and C with metastases, 7) was examined in short-term 51Cr-release assays, against fresh autologous tumour cells, allogeneic colon cancer cells and the erythroleukaemia cell line, K562. Cytotoxicity against autologous cells was detected in at least one effector population in 23/47 patients (49%), with overall frequencies which did not differ for patients in different Duke's stages of disease. By contrast, lysis of allogeneic tumour cells was infrequent (11%) regardless of the effector population to which they were exposed. Cytotoxicity against K562, cells highly sensitive to NK activity, though variable, was detected in 93% of PBL of normal donors and 83% of patients, and among the latter showed no evidence of significant decline with advancing disease. However, LNC and TIL anti-K562 activity was infrequent (17%) in concordance with previous reports. There was no correlation between the ability of patients' PBL to lyse autologous tumour and K562 cells. The independence of these 2 cytotoxic actions was further explored in studies fractionating lymphocytes: autologous tumour killing was augmented in T-enriched PBL; whereas the greatest anti-K562 activity was found in the corresponding non-T fraction. Lymphocyte cytotoxicity in colonic neoplasia is thus manifest in 2 apparently independent lymphocyte populations; a relatively specific killer T-cell population, detectable in PBL, LNC and TIL, which is preferentially reactive with the autologous cells; and a non-specific killer population, largely limited to PBL, with the properties of NK cells. The activity of neither population reflects the clinical status of patients with this disease.

PubMed Disclaimer

Similar articles

• Extravascular natural cytotoxicity in man: Anti-K562 activity of lymph-node and tumour-infiltrating lymphocytes.
  Moore M, Vose BM. Moore M, et al. Int J Cancer. 1981 Mar 15;27(3):265-72. doi: 10.1002/ijc.2910270303. Int J Cancer. 1981. PMID: 6169658
• Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
  Tsujihashi H, Matsuda H, Uejima S, Akiyama T, Kurita T. Tsujihashi H, et al. J Urol. 1988 Oct;140(4):890-4. doi: 10.1016/s0022-5347(17)41851-9. J Urol. 1988. PMID: 3262173
• Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
  Allavena P, Introna M, Sessa C, Mangioni C, Mantovani A. Allavena P, et al. J Natl Cancer Inst. 1982 Apr;68(4):555-62. J Natl Cancer Inst. 1982. PMID: 6175786
• Comparison of the cellular cytotoxic activities of colostral lymphocytes and maternal peripheral blood lymphocytes.
  Nair MP, Schwartz SA, Slade HB, Johnson MZ, Quebbeman JF, Beer AE. Nair MP, et al. J Reprod Immunol. 1985 May;7(3):199-213. doi: 10.1016/0165-0378(85)90051-8. J Reprod Immunol. 1985. PMID: 2410614 Review.
• Activation of lymphocyte anti-tumour responses in man: effector heterogeneity and the search for immunomodulators.
  Vose BM. Vose BM. Cancer Metastasis Rev. 1987;5(4):299-312. doi: 10.1007/BF00055375. Cancer Metastasis Rev. 1987. PMID: 3552279 Review.

Cited by

• Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
  Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA. Turcotte S, et al. J Immunol. 2013 Sep 1;191(5):2217-25. doi: 10.4049/jimmunol.1300538. Epub 2013 Jul 31. J Immunol. 2013. PMID: 23904171 Free PMC article.
• Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis.
  Håkansson L, Adell G, Boeryd B, Sjögren F, Sjödahl R. Håkansson L, et al. Br J Cancer. 1997;75(3):374-80. doi: 10.1038/bjc.1997.61. Br J Cancer. 1997. PMID: 9020482 Free PMC article.
• Biological significance of autologous tumor-killing activity and its induction therapy.
  Uchida A. Uchida A. Cancer Immunol Immunother. 1993 Jul;37(2):75-83. doi: 10.1007/BF01517038. Cancer Immunol Immunother. 1993. PMID: 8319244 Free PMC article. Review.
• A trial of nonspecific immunotherapy using systemic C. parvum in treated patients with Dukes B and C colorectal cancer.
  Souter RG, Gill PG, Morris PJ. Souter RG, et al. Br J Cancer. 1982 Apr;45(4):506-12. doi: 10.1038/bjc.1982.86. Br J Cancer. 1982. PMID: 7041943 Free PMC article. Clinical Trial.

References

1. 1. Br Med J. 1971 Dec 18;4(5789):706-9 - PubMed
2. 1. J Exp Med. 1981 Mar 1;153(3):569-82 - PubMed
3. 1. J Natl Cancer Inst. 1973 Feb;50(2):535-8 - PubMed
4. 1. Cancer Res. 1973 Nov;33(11):2898-902 - PubMed
5. 1. Eur J Immunol. 1973 Oct;3(10):645-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database